Equity Capital Markets
CytomX Therapeutics Inc.
05/25
|
$100.0 Million
Âé¶¹´«Ã½ served as bookrunner for CytomX Therapeutics Inc. on its RD
Sub-Type
Registered Direct
Sector
Sub-Sector
Biopharma